about
Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1aIs it time to target no evident disease activity (NEDA) in multiple sclerosis?Neuroprotection in a novel mouse model of multiple sclerosisBrain health: time matters in multiple sclerosisPlacebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosisGenomic regions associated with multiple sclerosis are active in B cellsA randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosisAlemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trialThe diagnostic criteria for multiple sclerosis: From Charcot to McDonald.Emerging therapies in multiple sclerosis.Correlating immunological and magnetic resonance imaging markers of disease activity in multiple sclerosis.Delayed-release dimethyl fumarate and disability assessed by the Multiple Sclerosis Functional Composite: Integrated analysis of DEFINE and CONFIRM.Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies.An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis.Matrix metalloproteinases in inflammatory demyelination: targets for treatment.Multiple sclerosis and its treatment.Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI.Smoking and multiple sclerosis: an updated meta-analysisA service development study of the assessment and management of fracture risk in Parkinson's diseaseProtease-activated receptor-1 activation by granzyme B causes neurotoxicity that is augmented by interleukin-1βImmunological surrogate markers of disease activity in multiple sclerosis.Comparative utility of disability progression measures in PPMS: Analysis of the PROMiSe data set.Reduction in Healthcare and Societal Resource Utilization Associated with Cladribine Tablets in Patients with Relapsing-Remitting Multiple Sclerosis : Analysis of Economic Data from the CLARITY Study.Bacterial vaccines for the treatment of multiple sclerosis and other autoimmune disorders.A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies.Effects of delayed-release dimethyl fumarate on MRI measures in the Phase 3 DEFINE study.Tourette's syndrome: a cross sectional study to examine the PANDAS hypothesis.The therapeutic potential of cannabis.Meta-analysis of the relationship between multiple sclerosis and migraineAge-associated hyper-methylated regions in the human brain overlap with bivalent chromatin domainsIntegrating multiple oestrogen receptor alpha ChIP studies: overlap with disease susceptibility regions, DNase I hypersensitivity peaks and gene expression.Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE studyNo evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis.Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients.Are antibasal ganglia antibodies important, and clinically useful?Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS.Antineuronal antibody status and phenotype analysis in Tourette's syndrome.
P50
Q24805642-8C3A4792-ECE4-4374-9155-7C4BFC40703DQ26801550-461C4BC3-2C4D-4A32-938A-2AC1E1AC6808Q27302918-56F294D9-D302-40C9-8A9A-A092CE0225A3Q28076642-90D85000-CFB1-406F-B2A1-CB11296F011CQ28275399-19F616DF-4FAB-4AF2-9A3A-28632984D16EQ28731577-F010AC60-C365-4CF9-8F5A-D4A338182AC8Q29616119-054491DC-94BC-41A3-B774-D91CD28DE5C0Q30053056-AD0AE652-A355-4625-AD80-2AB4AC0FD3ECQ30932774-5461F29F-4D15-45F3-A5EF-41041C2CEC23Q31015100-8D933A22-85CA-4E23-B163-CEC988EAD76AQ32059017-8CB61FC1-1D01-4D45-A8F2-92DDCC9CE1BCQ33613287-F4C652EC-DA8B-490F-8B15-20A1FF5D9B22Q33627259-08846E1E-43FF-4B19-B9AC-4D3D534A2FBCQ33628626-AA46A2A8-1A88-46BC-B81B-DB23493692F5Q33687084-0584B852-F6A8-4F9C-A297-978FC7D04532Q33688698-7E5888D4-1523-4941-B58E-9CE230F6644FQ33725422-B1B22D71-4F1F-441B-8AEF-C87E18544183Q33765725-E719FC3F-1E8F-4CC5-AD05-481351FC8A0AQ33797795-FC1B303E-A4D4-4B8A-9A9F-D275BE5E772BQ33813275-F90AE114-E373-4873-A7FA-12AE5BECD017Q33846630-0A8C1B37-925F-4A11-B556-75FED1AAF6BFQ33846942-DAC4E117-256B-472D-A575-7BE373332E93Q33848186-5E4D9E53-4644-4CD9-AFE1-914D76839156Q34053766-87818E5B-3994-4B4E-B45B-FCCCC9558E9CQ34079330-D015FCCD-AF94-4979-A814-FEEC3FECDBBBQ34093899-92E61CCD-38FF-475E-8E57-FA72F242A1B3Q34101598-0BFA3BE6-F9C2-43B3-9EB5-0B8A8ABFE91EQ34136565-506FE463-364F-4BB2-9BD7-D518B87DF18FQ34191203-59B7B396-0802-431D-A0D8-3CEFC20F9AF9Q34212503-8951AAB8-753C-4794-9836-4709F772A75EQ34425324-A745F6DF-2706-4B4D-A4BE-74D6969D84E8Q34426847-6891A98A-DE49-45C5-A3DC-85FD9AAF7444Q34493813-F76D53C0-9225-4710-B4D6-C7A5537944E9Q34567372-CB1936F6-A76F-44EE-B0B8-D2252D08CA5AQ34577661-EF327DD3-CA48-4838-B226-39CEC5BBE648Q34606170-06FDDB23-8FE3-45DB-A87A-2699FC288663Q34618602-6606D60C-F3D0-485A-8C19-2DE6A88C88BEQ34619715-DC2BB46E-45E4-438E-B883-101C6EC834C9Q34621839-40545BBD-D4CB-4AC7-9F57-BA0B4E4581F8Q34630405-960E335F-0F16-414A-8361-2617EB52671C
P50
description
researcher ORCID ID = 0000-0001-9995-1700
@en
wetenschapper
@nl
name
Gavin Giovannoni
@ast
Gavin Giovannoni
@en
Gavin Giovannoni
@es
Gavin Giovannoni
@nl
type
label
Gavin Giovannoni
@ast
Gavin Giovannoni
@en
Gavin Giovannoni
@es
Gavin Giovannoni
@nl
prefLabel
Gavin Giovannoni
@ast
Gavin Giovannoni
@en
Gavin Giovannoni
@es
Gavin Giovannoni
@nl
P31
P496
0000-0001-9995-1700